LLY

725.05

+0.04%↑

JNJ

180.79

+0.64%↑

ABBV

221.65

+0.42%↑

UNH

343.61

-0.16%↓

NVO

55.33

-0.49%↓

LLY

725.05

+0.04%↑

JNJ

180.79

+0.64%↑

ABBV

221.65

+0.42%↑

UNH

343.61

-0.16%↓

NVO

55.33

-0.49%↓

LLY

725.05

+0.04%↑

JNJ

180.79

+0.64%↑

ABBV

221.65

+0.42%↑

UNH

343.61

-0.16%↓

NVO

55.33

-0.49%↓

LLY

725.05

+0.04%↑

JNJ

180.79

+0.64%↑

ABBV

221.65

+0.42%↑

UNH

343.61

-0.16%↓

NVO

55.33

-0.49%↓

LLY

725.05

+0.04%↑

JNJ

180.79

+0.64%↑

ABBV

221.65

+0.42%↑

UNH

343.61

-0.16%↓

NVO

55.33

-0.49%↓

Search

Biogen Inc

Open

SectorHealthcare

137.05 -0.27

Overview

Share price change

24h

Current

Min

135.28

Max

137.42

Key metrics

By Trading Economics

Income

394M

635M

Sales

215M

2.6B

P/E

Sector Avg

13.46

35.69

EPS

3.02

Profit margin

23.995

Employees

7,605

EBITDA

457M

1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+21.72% upside

Dividends

By Dow Jones

Next Earnings

29 Oct 2025

Market Stats

By TradingEconomics

Market Cap

1.9B

21B

Previous open

137.32

Previous close

137.05

News Sentiment

By Acuity

50%

50%

131 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Biogen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Sept 2025, 18:25 UTC

Major Market Movers

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 Sept 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 Sept 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 Sept 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 Sept 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27 Sept 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 Sept 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 Sept 2025, 20:54 UTC

Earnings

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 Sept 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 Sept 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 Sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 Sept 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 Sept 2025, 19:53 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 Sept 2025, 19:40 UTC

Earnings

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 Sept 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 Sept 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 Sept 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 Sept 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 Sept 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 Sept 2025, 18:50 UTC

Market Talk
Earnings

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 Sept 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 Sept 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 Sept 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 Sept 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 Sept 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 Sept 2025, 16:56 UTC

Market Talk
Earnings

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 Sept 2025, 16:41 UTC

Market Talk
Earnings

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 Sept 2025, 16:26 UTC

Earnings

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 Sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

21.72% upside

12 Months Forecast

Average 167.2 USD  21.72%

High 224 USD

Low 118 USD

Based on 26 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

26 ratings

12

Buy

14

Hold

0

Sell

Technical Score

By Trading Central

118.15 / 121.17Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

131 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat